Matches in SemOpenAlex for { <https://semopenalex.org/work/W4381377995> ?p ?o ?g. }
Showing items 1 to 76 of
76
with 100 items per page.
- W4381377995 abstract "Combined use of basal insulin (BI) and glucagon-like peptide 1 receptor agonist (GLP1-RA) deserves consideration for the synergistic effects on glucose profile. Nevertheless, it is unclear if the addition of BI to the ongoing GLP1-RA therapy in free or fixed combination is associated with different outcomes. Aim of this RESTORE-G sub-study was to perform a propensity-score adjusted comparative effectiveness analysis of the two most innovative BIs for intensifying GLP1-RA therapy (±oral agents), i.e. Glargine 300 U/mL in free combination (Gla-300) vs. the fixed ratio combination of insulin degludec + liraglutide (IDegLira). Table shows sample sizes, patients characteristics and effectiveness results. Compared to IDegLira, Gla-300 group had older age, worse metabolic control, and higher starting BI doses. After 6 months, statistically significant larger FBG reduction and BI dose increase were found in the free vs. fixed combination group. Trends of larger HbA1c and weight reductions with the free combination were also found, without reaching the statistical significance. In conclusion, higher benefits on FBG control in free vs. fixed combination has been found in people uncontrolled on GLP-1 RA, likely due to a better titration of the components. However, inertia in insulin initiation was documented in both groups. Disclosure R. Candido: None. A. Nicolucci: Board Member; AstraZeneca, Research Support; Novo Nordisk, Sanofi, Sobi, Shionogi & Co., Ltd., AlfaSigma, Speaker's Bureau; Boehringer Ingelheim and Eli Lilly Alliance. M. Rossi: Research Support; Sanofi, Novo Nordisk, Shionogi & Co., Ltd., AlfaSigma. M. Larosa: None. R. Napoli: Advisory Panel; Sanofi, Eli Lilly and Company, Novo Nordisk, Research Support; Novo Nordisk, AstraZeneca, Speaker's Bureau; Sanofi, Eli Lilly and Company, Novo Nordisk, AstraZeneca, MSD Life Science Foundation. Restore-g study group: n/a. Funding Sanofi" @default.
- W4381377995 created "2023-06-21" @default.
- W4381377995 creator A5010127891 @default.
- W4381377995 creator A5013993396 @default.
- W4381377995 creator A5039243906 @default.
- W4381377995 creator A5047681714 @default.
- W4381377995 creator A5071212146 @default.
- W4381377995 creator A5084691011 @default.
- W4381377995 date "2023-06-20" @default.
- W4381377995 modified "2023-10-18" @default.
- W4381377995 title "84-LB: Intensification of Glucagon-Like Peptide-1 Receptor Agonists Therapy with Glargine 300 U/mL or IDegLira—The RESTORE-G Real-World Study" @default.
- W4381377995 doi "https://doi.org/10.2337/db23-84-lb" @default.
- W4381377995 hasPublicationYear "2023" @default.
- W4381377995 type Work @default.
- W4381377995 citedByCount "0" @default.
- W4381377995 crossrefType "journal-article" @default.
- W4381377995 hasAuthorship W4381377995A5010127891 @default.
- W4381377995 hasAuthorship W4381377995A5013993396 @default.
- W4381377995 hasAuthorship W4381377995A5039243906 @default.
- W4381377995 hasAuthorship W4381377995A5047681714 @default.
- W4381377995 hasAuthorship W4381377995A5071212146 @default.
- W4381377995 hasAuthorship W4381377995A5084691011 @default.
- W4381377995 hasConcept C126322002 @default.
- W4381377995 hasConcept C126894567 @default.
- W4381377995 hasConcept C134018914 @default.
- W4381377995 hasConcept C170493617 @default.
- W4381377995 hasConcept C185280430 @default.
- W4381377995 hasConcept C2776398474 @default.
- W4381377995 hasConcept C2776442814 @default.
- W4381377995 hasConcept C2776999253 @default.
- W4381377995 hasConcept C2777180221 @default.
- W4381377995 hasConcept C2778938600 @default.
- W4381377995 hasConcept C2779306644 @default.
- W4381377995 hasConcept C2779920387 @default.
- W4381377995 hasConcept C2780668416 @default.
- W4381377995 hasConcept C2781308992 @default.
- W4381377995 hasConcept C2909524832 @default.
- W4381377995 hasConcept C555293320 @default.
- W4381377995 hasConcept C71924100 @default.
- W4381377995 hasConcept C98274493 @default.
- W4381377995 hasConceptScore W4381377995C126322002 @default.
- W4381377995 hasConceptScore W4381377995C126894567 @default.
- W4381377995 hasConceptScore W4381377995C134018914 @default.
- W4381377995 hasConceptScore W4381377995C170493617 @default.
- W4381377995 hasConceptScore W4381377995C185280430 @default.
- W4381377995 hasConceptScore W4381377995C2776398474 @default.
- W4381377995 hasConceptScore W4381377995C2776442814 @default.
- W4381377995 hasConceptScore W4381377995C2776999253 @default.
- W4381377995 hasConceptScore W4381377995C2777180221 @default.
- W4381377995 hasConceptScore W4381377995C2778938600 @default.
- W4381377995 hasConceptScore W4381377995C2779306644 @default.
- W4381377995 hasConceptScore W4381377995C2779920387 @default.
- W4381377995 hasConceptScore W4381377995C2780668416 @default.
- W4381377995 hasConceptScore W4381377995C2781308992 @default.
- W4381377995 hasConceptScore W4381377995C2909524832 @default.
- W4381377995 hasConceptScore W4381377995C555293320 @default.
- W4381377995 hasConceptScore W4381377995C71924100 @default.
- W4381377995 hasConceptScore W4381377995C98274493 @default.
- W4381377995 hasIssue "Supplement_1" @default.
- W4381377995 hasLocation W43813779951 @default.
- W4381377995 hasOpenAccess W4381377995 @default.
- W4381377995 hasPrimaryLocation W43813779951 @default.
- W4381377995 hasRelatedWork W2490399744 @default.
- W4381377995 hasRelatedWork W2592545469 @default.
- W4381377995 hasRelatedWork W2789621478 @default.
- W4381377995 hasRelatedWork W2789960392 @default.
- W4381377995 hasRelatedWork W2792302884 @default.
- W4381377995 hasRelatedWork W2793531770 @default.
- W4381377995 hasRelatedWork W2793811164 @default.
- W4381377995 hasRelatedWork W2801822172 @default.
- W4381377995 hasRelatedWork W2894692298 @default.
- W4381377995 hasRelatedWork W3048253389 @default.
- W4381377995 hasVolume "72" @default.
- W4381377995 isParatext "false" @default.
- W4381377995 isRetracted "false" @default.
- W4381377995 workType "article" @default.